Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631
Open Access
- 10 September 2017
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (26), 3021-3029
- https://doi.org/10.1200/jco.2016.71.6183
Abstract
Purpose The Children’s Oncology Group AAML0631 trial for newly diagnosed pediatric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the survival of patients receiving arsenic trioxide (ATO) consolidation and reduced doses of anthracyclines. Patients and Methods Patients age 2 to 21 years with de novo APL confirmed by PML-RARα polymerase chain reaction were stratified as standard risk (SR) or high risk (HR) on the basis of diagnostic WBC count. All patients received all-trans retinoic acid (ATRA) during induction, each consolidation course, and maintenance. All patients received two cycles of ATO therapy during consolidation 1, an additional two (SR) or three (HR) consolidation courses that included high-dose cytarabine and anthracycline, and maintenance therapy comprising ATRA, oral methotrexate, and mercaptopurine. Results One hundred one patients (66 SR and 35 HR) were evaluable for outcome. The 3-year overall survival was 94%, and event-free survival (EFS) was 91%. For SR and HR patients with APL, the overall survival was 98% versus 86% ( P = .003), and EFS was 95% versus 83% ( P = .03), respectively. The EFS for SR patients in AAML0631 was noninferior to that of patients in the AIDA 0493 historical control, which used a significantly higher anthracycline dose and did not include ATO consolidation. Relapse risk for patients in AAML0631 from end consolidation 1 (after ATO treatment) was only 4% at 3 years and did not differ significantly between SR and HR patients. Conclusion ATO consolidation cycles were well tolerated in pediatric patients with APL and allowed significant reduction in cumulative anthracycline doses while maintaining excellent survival and a low relapse risk for both SR and HR patients with APL.Keywords
This publication has 30 references indexed in Scilit:
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Blood, 2010
- Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapyHaematologica, 2009
- Treatment of children with acute promyelocytic leukemia: Results of the first North American intergroup trial INT0129Pediatric Blood & Cancer, 2009
- Therapy-Related Myeloid LeukemiaSeminars in Oncology, 2008
- Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology GroupPublished by American Academy of Pediatrics (AAP) ,2008
- GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in childrenPublished by American Society of Hematology ,2005
- Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experienceLeukemia, 2004
- Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemiaBritish Journal of Haematology, 1997
- CARDIAC TRANSPLANTATION FOR DOXORUBICIN‐INDUCED CARDIOMYOPATHY IN ACUTE MYELOID LEUKAEMIABritish Journal of Haematology, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958